Authors:

Jifang Gong¹ , Ning Li² , Weijian Guo³, Tianshu Liu⁴ , Hongli Li⁵ , Jiayi Li ⁶ , Zhenzhong Xia⁷ , Chunhua Qian ⁷ , Jenny Yao ⁸ , Jianming Wang ⁸ , Lijuan Zhang ⁷ , Chuan Qi ⁷ , Michael Shi ⁸ , Xu,Li ⁸ , Caroline Germa ⁸ , Xueming Qian ⁷ , Lin Shen ¹ ;

¹Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China; ²Henan Cancer Hospital, Zhengzhou, China; ³Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China; ⁴Zhongshan Hospital, Fudan University, Shanghai, China; ⁵Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; ⁶The First Affiliated Hospital of Xiamen University, Xiamen, China; ⁷Suzhou Transcenta Therapeutics Co., Ltd; ⁸Transcenta Therapeutics Inc.

Background:

TST001 is a recombinant humanized antibody that can specifically bind to the  extracellular structure of Claudin18.2 (CLDN18.2) protein and eliminate cancer cells  by antibody-dependent cellular cytotoxicity and complement-dependent  cytotoxicity.  

Pre-clinical studies have shown that TST001 has synergistic effect when used in  combination with chemotherapy.

Conclusions:

TST001 in combination with CAPOX as the first line treatment of patients with G/GEJ  cancer is well tolerated and encouraging anti-tumor activities have been observed.  CLDN18.2 expression thresholds and correlation with efficacy are being further  assessed.